Loading organizations...
China Life Capital is an investment and asset management firm based in the Shanghai Free Trade Zone, China, that focuses on private securities and improving long-term capital utilization efficiency. Operating as a wholly-owned subsidiary of China Life Insurance Company, the firm manages capital and diversifies investment assets for its state-owned parent organization. In 2023, the firm deployed $3.5 billion into the Honghu Private Securities Investment Fund alongside an equal financial contribution from its parent entity. The organization leverages the extensive financial infrastructure of the broader China Life Insurance group, which includes subsidiaries spanning property and casualty insurance, pension services, and banking. This parent group ranked 94th on the Fortune Global 500 list and 62nd on the Forbes Global 2000 list. China Life Capital was founded in 2016 as a corporate subsidiary without individual founders.
The firm focuses on private securities investment and operates as an equity investment fund management platform, managing real asset equity funds.
The firm focuses on private securities investment and operates as an equity investment fund management platform, managing real asset equity funds.
China Life Capital has 2 tracked investments across 2 companies. The latest tracked deal is $43.4M Series A in Zhiran Medical in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2026 | Zhiran Medical | $43.4M Series A | CAS Star, IDG Capital, Legend Capital | Apricot Capital, Baidu Ventures, Beijing Medical And Health Industry Investment Fund, BioVenture, Jiayin Capital, Lenovo Capital And Incubator Group (LCIG), Longzhu Capital, Sequoia Capital, Shunwei Capital, Beijing Pharmaceutical And Health Industry Investment Fund, DragonBall Capital |
| Feb 10, 2026 | Cascade | $72.3M Venture Round | Zhongping Capital | Gaorong Capital, Kangjun Capital, Qingdao Guoxin, Qingsong Capital, Shanghai Guotou Pioneer |
